Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page
- Check5 days agoChange DetectedA new study version v3.6.0 was posted with a recruitment-status update indicating no longer looking for participants, and the previous version v3.5.5 was removed from the history.SummaryDifference0.4%

- Check12 days agoChange DetectedThe record history now shows the latest revision as v3.5.5, replacing the previous v3.5.4 entry in the changes list.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedAn additional revision entry, v3.5.4, was added to the Study Record History, extending the version history after v3.5.3. The previous revision v3.5.3 has been removed from the current change set.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page’s footer/site revision label has been updated from v3.5.2 to v3.5.3, indicating a minor platform/version change without altering the clinical trial record shown.SummaryDifference0.1%

- Check61 days agoChange DetectedAdded Revision: v3.5.2 and deleted Revision: v3.5.0 in the study record history.SummaryDifference0.1%

- Check91 days agoChange DetectedAdded Revision: v3.5.0; Removed Revision: v3.4.3 in the record history.SummaryDifference0.1%

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.